First launch for Daiichi Sankyo's long-acting inhaled flu drug
This article was originally published in Scrip
Daiichi Sankyo has launched in Japan the long-acting inhaled neuraminidase inhibitor, Inavir (laninamivir octanoate hydrate), for the treatment of A and B type flu infections.
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?